Shares of Biogen Inc. BIIB inched 0.31% higher to $150.49 Monday, on what proved to be an all-around mixed trading session ...

Shares of Biogen Inc. BIIB inched 0.10% higher to $150.64 Tuesday, on what proved to be an all-around grim trading session ...

The Centers for Medicare & Medicaid Services has directed private insurers providing Medicare Advantage plans to cover Biogen ...

CMS has reportedly directed Medicare Advantage plan providers to cover Biogen's drug Qalsody for ALS following reports it was ...

In a rare move, the U.S. agency behind Medicare is warning Medicare Advantage providers they can’t have blanket policies that ...

Biogen (BIIB) closed near a 52-week low of $150.03. The stock trades at a discount because the biotech firm lacks growth ...

Jefferies downgraded Biogen Inc (NASDAQ:BIIB), citing the company’s tough setup. Leqembi (lecanemab) sales growth remains ...

Stifel downgraded Biogen Inc (NASDAQ:BIIB) stock to “hold” from “buy” as it noted the company was grappling with a challenging year due to a slow rollout of its Alzheimer’s drug, lecanemab.

Biogen Inc. (BIIB), headquartered in Cambridge, Massachusetts, with a market cap of $21.9 billion, is a leading biotechnology ...

Analysts have recently evaluated Biogen and provided 12-month price targets. The average target is $241.79, accompanied by a ...

Stifel Nicolaus lowered shares of Biogen (NASDAQ:BIIB – Free Report) from a buy rating to a hold rating in a research report sent to investors on Monday, MarketBeat.com reports. Stifel Nicolaus ...

Fintel reports that on December 9, 2024, Jefferies downgraded their outlook for Biogen (NasdaqGS:BIIB) from Buy to Hold.